Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma

Completed · Phase 1/Phase 2

Conditions studied: Intraocular Melanoma, Melanoma (Skin)

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of melanoma by stopping blood flow to the tumor. Combining chemotherapy with thalidomide may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness temozolomide plus thalidomide in treating patients who have stage III or stage IV melanoma that cannot be removed during surgery.

Key facts

Study ID

NCT00005815

Run by

Memorial Sloan Kettering Cancer Center

Starts

1999-12-01

Expected to finish

2004-08-01

Last updated by the study team

2013-06-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Memorial Sloan-Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.